Physician profile
Roberto Saez
NPI 1811925910
$8,494.73
in general payments reported to CMS, 2019-2025
47 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $1,320 · 2021: $1,637 · 2022: $1,118 · 2023: $1,300 · 2024: $1,067 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,187.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,387.15 | 2021-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $766.66 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $755.30 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $560.51 | 2020-2025 | Freestyle Libre, Freestyle Libre 3 |
| Pfizer INC. | $557.55 | 2019-2025 | |
| Novo Nordisk INC | $430.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $351.72 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $333.31 | 2019-2025 | Breztri |
| Kowa Pharmaceuticals America, INC. | $330.97 | 2019-2022 | |
| Astellas Pharma US INC | $305.25 | 2019-2024 | Veozah, Myrbetriq |
| Allergan, INC. | $257.52 | 2019-2020 | |
| Gilead Sciences, INC. | $224.45 | 2019-2023 | Biktarvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.02 | 2019-2024 | Ofev |
| Lilly USA, LLC | $146.86 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $145.74 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Saez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.